Epidemiology and optimal management in patients with renal artery stenosis

Journal of Nephrology

Volumn 25, Issue 6, 2012, Pages 872-878

  Piecha, Grzegorz ^a   Wiecek, Andrzej ^a   Januszewicz, Andrzej ^b  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

Antihypertensive drugs; Atherosclerosis; Revascularization

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE COURSE; DOPPLER ECHOGRAPHY; DRUG EFFICACY; HUMAN; HYPERTENSION; IMAGE ANALYSIS; KIDNEY ARTERY STENOSIS; MAGNETIC RESONANCE ANGIOGRAPHY; MEDICAL DECISION MAKING; POSTOPERATIVE HEMORRHAGE; PREVALENCE; RENOVASCULAR HYPERTENSION; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ANGIOPLASTY; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, RENOVASCULAR; PATIENT SELECTION; PREVALENCE; RENAL ARTERY OBSTRUCTION; RISK FACTORS; STENTS; TREATMENT OUTCOME;

EID: 84870619912     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000206     Document Type: Review

References (63)

1. Hansen KJ, Edwards MS, Craven TE, et al. Prevalence of renovascular disease in the elderly: a population-based study. J Vasc Surg. 2002;36(3):443-451.
2. Khosla S, Kunjummen B, Manda R, et al. Prevalence of renal artery stenosis requiring revascularization in patients initially referred for coronary angiography. Catheter Cardiovasc Interv. 2003;58(3):400-403.
3. Mac Dowall P, Kalra PA, O'Donoghue DJ, Waldek S, Mamtora H, Brown K. Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. Lancet. 1998;352(9121):13-16.
4. Olin JW, Melia M, Young JR, Graor RA, Risius B. Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere. Am J Med. 1990;88(1N):46N-51N.
5. Mancia G, De Backer G, Dominiczak A, et al; Management of Arterial Hypertension of the European Society of Hyper-of Cardiology (ESC). J Hypertens. 2007;25(6):1105-1187.
6. Schwartz CJ, White TA. Stenosis of Renal Artery: an unselected necropsy study. BMJ. 1964;2(5422):1415-1421.
7. Jain S, Kumari S, Ganguly NK, Sharma BK. Current status of Takayasu arteritis in India. Int J Cardiol. 1996;54(Suppl): S111-S116.
8. de Mast Q, Beutler JJ. The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review. J Hypertens. 2009;27(7):1333-1340.
9. Nicholson JP, Teichman SL, Alderman MH, Sos TA, Pickering TG, Laragh JH. Cigarette smoking and renovascular hypertension. Lancet. 1983;2(8353):765-766.
10. Black HR, Cooper KA. Cigarette smoking and atherosclerotic renal artery stenosis. J Clin Hypertens. 1986;2(4): 322-330.
11. Jazrawi A, Darda S, Burke P, et al. Is race a risk factor for the development of renal artery stenosis? Cardiol Res Pract. 2009;2009:817987.
12. Svetkey LP, Kadir S, Dunnick NR, et al. Similar prevalence of renovascular hypertension in selected blacks and whites. Hypertension. 1991;17(5):678-683.
13. Kalra PA, Guo H, Kausz AT, et al. Atherosclerotic renovascular disease in United States patients aged 67 years or older: risk factors, revascularization, and prognosis. Kidney Int. 2005;68(1):293-301.
14. Börgel J, Springer S, Ghafoor J, et al. Unrecognized secondary causes of hypertension in patients with hypertensive urgency/emergency: prevalence and co-prevalence. Clin Res Cardiol. 2010;99(8):499-506.
15. Green D, Kalra PA. The heart in atherosclerotic renovascular disease. Front Biosci (Elite Ed). 2012;4:856-864.
16. Cheung CM, Wright JR, Shurrab AE, et al. Epidemiology of renal dysfunction and patient outcome in atherosclerotic renal artery occlusion. J Am Soc Nephrol. 2002;13(1):149-157.
17. Dwyer KM, Vrazas JI, Lodge RS, et al. Treatment of acute renal failure caused by renal artery occlusion with renal artery angioplasty. Am J Kidney Dis. 2002;40(1):189-194.
18. Pearce JD, Craven BL, Craven TE, et al. Progression of atherosclerotic renovascular disease: a prospective populationbased study. J Vasc Surg. 2006;44(5):955-962, discussion 962-963.
19. Conlon PJ, Little MA, Pieper K, Mark DB. Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney Int. 2001;60(4):1490-1497.
20. van Jaarsveld BC, Krijnen P, Pieterman H, et al; Dutch Renal Artery Stenosis Intervention Cooperative Study Group. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. N Engl J Med. 2000;342(14): 1007-1014.
21. Wheatley K, Ives N, Gray R, et al; ASTRAL Investigators. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. 2009;361(20):1953-1962.
22. Harden PN, MacLeod MJ, Rodger RS, et al. Effect of renal-artery stenting on progression of renovascular renal failure. Lancet. 1997;349(9059):1133-1136.
23. Wright JR, Shurrab AE, Cheung C, et al. A prospective study of the determinants of renal functional outcome and mortality in atherosclerotic renovascular disease. Am J Kidney Dis. 2002;39(6):1153-1161.
24. Textor SC. Renovascular hypertension in 2007: where are we now? Curr Cardiol Rep. 2007;9(6):453-461.
25. Chrysochou C, Cheung CM, Durow M, et al. Proteinuria as a predictor of renal functional outcome after revascularization in atherosclerotic renovascular disease (ARVD). QJM. 2009;102(4):283-288.
26. Chrysochou C, Kalra PA. Epidemiology and natural history of atherosclerotic renovascular disease. Prog Cardiovasc Dis. 2009;52(3):184-195.
27. Hansen KJ, Tribble RW, Reavis SW, et al. Renal duplex sonography: evaluation of clinical utility. J Vasc Surg. 1990;12(3):227-236.
28. Kohler TR, Zierler RE, Martin RL, et al. Noninvasive diagnosis of renal artery stenosis by ultrasonic duplex scanning. J Vasc Surg. 1986;4(5):450-456.
29. Rountas C, Vlychou M, Vassiou K, et al. Imaging modalities for renal artery stenosis in suspected renovascular hypertension: prospective intraindividual comparison of color Doppler US, CT angiography, GD-enhanced MR angiography, and digital substraction angiography. Ren Fail. 2007;29(3): 295-302.
30. Chrysochou C, Mendichovszky I A, Buckley DL, Cheung CM, Jackson A, Kalra PA. BOLD imaging: a potential predictive biomarker of renal functional outcome following revascularization in atheromatous renovascular disease. Nephrol Dial Transplant. 2012;27(3):1013-1019.
31. Colyer WR Jr, Cooper CJ. Management of renal artery stenosis: 2010. Curr Treat Options Cardiovasc Med. 2011;13(2):103-113.
32. Hiramoto J, Hansen KJ, Pan XM, Edwards MS, Sawhney R, Rapp JH. Atheroemboli during renal artery angioplasty: an ex vivo study. J Vasc Surg. 2005;41(6):1026-1030.
33. Kanjwal K, Cooper CJ, Virmani R, et al. Predictors of embolization during protected renal artery angioplasty and stenting: role of antiplatelet therapy. Catheter Cardiovasc Interv. 2010;76(1):16-23.
34. Huskey J, Lindenfeld J, Cook T, et al. Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis. 2009;205(1):202-206.
35. Shah S, Paparello J, Danesh FR. Effects of statin therapy on the progression of chronic kidney disease. Adv Chronic Kidney Dis. 2005;12(2):187-195.
36. Baigent C, Landray MJ, Reith C, et al; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebocontrolled trial. Lancet. 2011;377(9784):2181-2192.
37. Cheung CM, Patel A, Shaheen N, et al. The effects of statins on the progression of atherosclerotic renovascular disease. Nephron Clin Pract. 2007;107(2):c35-c42.
38. Chade AR, Zhu XY, Grande JP, Krier JD, Lerman A, Lerman LO. Simvastatin abates development of renal fibrosis in experimental renovascular disease. J Hypertens. 2008; 26(8):1651-1660.
39. Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135(2):73-87.
40. Tendera M, Aboyans V, Bartelink ML, et al; European Stroke Organisation; Authors/Task Force Members; ESC Committee for Practice Guidelines; Document Reviewers. ESC guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22): 2851-2906.
41. Losito A, Errico R, Santirosi P, Lupattelli T, Scalera GB, Lupattelli L. Long-term follow-up of atherosclerotic renovascular disease:beneficial effect of ACE inhibition. Nephrol Dial Transplant. 2005;20(8):1604-1609.
42. Chrysochou C, Foley RN, Young JF, Khavandi K, Cheung CM, Kalra PA. Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease. Nephrol Dial Transplant. 2012;27(4):1403-1409.
43. Hackam DG, Duong-Hua ML, Mamdani M, et al. Angiotensin inhibition in renovascular disease: a population-based cohort study. Am Heart J. 2008;156(3):549-555.
44. van de Ven PJ, Beutler JJ, Kaatee R, Beek FJ, Mali WP, Koomans HA. Angiotensin converting enzyme inhibitorinduced renal dysfunction in atherosclerotic renovascular disease. Kidney Int. 1998;53(4):986-993.
45. Hackam DG, Spence JD, Garg AX, Textor SC. Role of reninangiotensin system blockade in atherosclerotic renal artery stenosis and renovascular hypertension. Hypertension. 2007;50(6):998-1003.
46. Johansson M, Elam M, Rundqvist B, et al. Increased sympathetic nerve activity in renovascular hypertension. Circulation. 1999;99(19):2537-2542.
47. Johansson M, Herlitz H, Jensen G, Rundqvist B, Friberg P. Increased cardiovascular mortality in hypertensive patients with renal artery stenosis. Relation to sympathetic activation, renal function and treatment regimens. J Hypertens. 1999;17(12 Pt 1):1743-1750.
48. Cianci R, Martina P, Borghesi F, et al. Revascularization versus medical therapy for renal artery stenosis: antihypertensive drugs and renal outcome. Angiology. 2011;62(1):92-99.
49. Duranay M, Kanbay M, Akay H, et al. Nebivolol improves renal function in patients who underwent angioplasty due to renal artery stenosis: a pilot study. Nephron Clin Pract. 2010;114(3):c213-c217.
50. Webster J, Marshall F, Abdalla M, et al; Scottish and Newcastle Renal Artery Stenosis Collaborative Group. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. J Hum Hypertens. 1998;12(5):329-335.
51. Plouin PF, Chatellier G, Darné B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group. Hypertension. 1998;31(3):823-829.
52. Bax L, Woittiez AJ, Kouwenberg HJ, et al. Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial. Ann Intern Med. 2009;150(12):840-848, W150-151.
53. Dorros G, Prince C, Mathia kL. Stenting of a renal artery stenosis achieves better relief of the obstructive lesion than balloon angioplasty. Cathet Cardiovasc Diagn. 1993;29(3):191-198.
54. Rundback JH, Manoni T, Rozenblit GN, et al. Balloon angioplasty or stent placement in patients with azotemic renovascular disease: a retrospective comparison of clinical outcomes. Heart Dis. 1999;1(3):121-125.
55. Lederman RJ, Mendelsohn FO, Santos R, Phillips HR, Stack RS, Crowley JJ. Primary renal artery stenting: characteristics and outcomes after 363 procedures. Am Heart J. 2001;142(2):314-323.
56. Kumbhani DJ, Bavry AA, Harvey JE, et al. Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: a meta-analysis of randomized controlled trials. Am Heart J. 2011;161(3):622-630.
57. Khosla S, Ahmed A, Siddiqui M, et al. Safety of angiotensinconverting enzyme inhibitors in patients with bilateral renal artery stenosis following successful renal artery stent revascularization. Am J Ther. 2006;13(4):306-308.
58. Cooper CJ, Murphy TP, Matsumoto A, et al. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J. 2006;152(1):59-66.
59. Marcantoni C, Zanoli L, Rastelli S, et al. Stenting of renal artery stenosis in coronary artery disease (RAS-CAD) study: a prospective, randomized trial. J Nephrol. 2009;22(1):13-16.
60. Schwarzwälder U, Hauk M, Zeller T. RADAR: a randomised, multi-centre, prospective study comparing best medical treatment versus best medical treatment plus renal artery stenting in patients with haemodynamically relevant atherosclerotic renal artery stenosis. Trials. 2009;10(1):60.
61. Leertouwer TC, Gussenhoven EJ, Bosch JL, et al. Stent placement for renal arterial stenosis: where do we stand? A meta-analysis. Radiology. 2000;216(1):78-85.
62. Corriere MA, Edwards MS, Pearce JD, et al. Restenosis after renal artery angioplasty and stenting: incidence and risk factors. J Vasc Surg. 2009;50(4):813-819.
63. Zähringer M, Sapoval M, Pattynama PM, et al. Sirolimus-eluting versus bare-metal low-profile stent for renal artery treatment (GREAT Trial): angiographic follow-up after 6 months and clinical outcome up to 2 years. J Endovasc Ther. 2007;14(4): 460-468.